Medi-Exametazim

Exametazime, the active ingredient in Medi-Exametazim, is a radiopharmaceutical presented as an injection solution for intravenous use. It enables cerebral perfusion imaging to assist diagnosis in patients with stroke, epilepsy or dementia. GNH USA supplies Medi-Exametazim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Medi-Exametazim is used in diagnostic imaging of cerebral blood flow for several neurological conditions.

Stroke evaluation: provides quantitative brain perfusion data to guide acute and sub‑acute stroke management. Epilepsy assessment: visualises regional cerebral perfusion patterns that help localise seizure foci. Dementia evaluation: assists in differentiating vascular from neurodegenerative causes by mapping perfusion deficits.

Medi-Exametazim may cause adverse reactions following intravenous administration.

Common Side Effects: - Injection site pain or erythema - Mild nausea or vomiting - Transient headache - Dizziness or light‑headedness - Flushing or warmth sensation - Temporary hypotension

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Severe hypotension requiring medical intervention - Pulmonary edema - Cardiac arrhythmias - Acute renal impairment - Severe skin reactions such as Stevens‑Johnson syndrome

Prior to use, clinicians should evaluate patient history and current condition.

Allergy assessment: confirm no known hypersensitivity to technetium‑99m or exametazime. Pregnancy considerations: avoid unless benefits outweigh potential risks. Renal function: assess in patients with impaired kidney function. Concurrent radiopharmaceuticals: avoid overlapping studies that may interfere with imaging. Drug interactions: review concomitant medications that could affect hemodynamics. Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Exametazime may interact with other agents that influence radiotracer distribution or cardiovascular stability.

Major Interactions (Avoid): - Other technetium‑99m labeled agents: competition for binding sites. - Strong reducing agents: may destabilise the Tc‑99m complex. - High‑dose iodine compounds: can alter biodistribution.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypotensive responses. - Sedatives or anxiolytics: can increase dizziness or fainting risk. - Iodinated contrast media: may affect image quality if administered close in time.